Finding Specialists and Paying for Services
- Introduction to Clinical Trials
- Research Findings
- Studies Enrolling Patients
- Research Collaborations
Follow Us!
PARP Inhibitor Ovarian Cancer Clinical Trials
PARP Inhibitor Ovarian Cancer Clinical Trials
Listed below are PARP Inhibitor studies that are currently enrolling patients with ovarian, fallopian tube, or primary peritoneal cancer. For more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.
- NCT01237067: Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
- NCT01482715: A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
- NCT00647062: AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer
- NCT01311713: Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
- NCT01012817: ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- NCT01306032: ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
- NCT00892736: ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
- NCT01281150: Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- NCT00989651: Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- NCT01286987: Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Page updated 01/11/12
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.